Discovery of a Secretory Granule Lumen-Enriched Serum Protein Signature in Resectable Pancreatic Ductal Adenocarcinoma
A three-protein blood test shows promise for detecting pancreatic cancer early, though it still needs testing in larger, diverse patient groups before use in clinics.
Using mass spectrometry-based serum proteomics in 35 resectable PDAC cases and 34 controls, researchers identified 90 differentially abundant proteins dominated by secretory granule lumen components. A three-protein panel (ITIH3, F13A1, FTL) showed AUC 0.98 in the discovery cohort, though external validation against pancreatitis controls and CA19-9 is required before clinical application.
What the study was
- Study design
- Discovery-phase proteomics case-control
- Population
- Resectable non-metastatic PDAC patients vs non-cancer controls without hepato-biliary-pancreatic disease
- Sample size
- 69
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Medicina (Kaunas)
Why it surfaced
Compelling early-detection signal for pancreatic cancer at resectable stage (high unmet need); discovery cohort only with possible feature-selection bias acknowledged by authors; requires independent validation before pipeline escalation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.